Abstract: An ophthalmic lens system for improving the vision of a patient comprising first and second ophthalmic lenses. Each of these lenses is adapted for implantation in an eye or to be disposed on or in the cornea. The first ophthalmic lens is biased for distance vision and the second ophthalmic lens is biased for intermediate vision. The ophthalmic lenses may be intraocular lenses which are implanted in the eyes of a patient without removal of the natural lens.

Abstract: A method for treating hypothyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a thyroid, thereby reducing an inhibitory effect upon thyroid hormone secretion. A method for treating hyperthyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates the thyroid, thereby reducing a stimulatory effect upon thyroid hormone secretion. Methods for treating calcium metabolism disorders by local administration of a neurotoxin to modulate calcitonin secretion are also disclosed.

Abstract: An intraocular lens configured to be implanted in the cornea from the posterior aspect. The lens has an optic and a pair fixation members extending outward therefrom. One of the fixation members includes a single enlarged foot, while the other fixation member has two bifurcated feet. The fixation members are sized and shaped to fix within tunnels formed in the cornea. A method of the invention includes forming tunnels in the stroma layer of the cornea, and positioning the fixation members in the tunnels. The tunnels may be formed from outside or inside the cornea. The method may include inserting the folded intraocular lens into the anterior chamber, permitting the lens to unfold, inserting the fixation member with the enlarged foot in one of the tunnels, and bending the two bifurcated feet of the other fixation member together so as to fit within the other tunnel.

Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; 1

Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; 1

Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.

Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.

Abstract: Methods and compounds for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects. Also included are methods of making and using such compounds.

Abstract: An intraocular lens having an optic portion and a plurality of fixation members coupled thereto. The optic portion includes an optic and a pair of outwardly extending flanges. The fixation members are relatively more rigid than the optic and attach to the flanges. The flanges provide lines of force transmission between pairs of fixation members so that compressive forces are not transmitted through the optic, therefore reducing vaulting. The fixation members may be bonded or mated to the flanges. A bridge between two opposed fixation members may be provided to form a fixation system, the bridges being attached to the flanges.

Abstract: Methods to identify agents having ocular hypotensive activity which have reduced or absent ability to stimulate iridial hyperpigmentation are disclosed. The methods reside in part in detecting the ability of a test compound to interact with the FP receptor.

Abstract: A controlled release system for multiphasic, in vivo release of therapeutic amounts of botulinum toxin in a human patient over a prolonged period of time. The controlled release system can comprise a plurality of botulinum toxin incorporating polymeric microspheres.

Abstract: Methods and ophthalmic compositions comprising a lipophilic drug in aqueous formulation with cyclodextrin or a cyclodextrin derivative.

Abstract: Compositions comprising a therapeutic component and an efficacy enhancing component that enhances the pharmacokinetic disposition of the therapeutic component is disclosed. In one embodiment, the therapeutic component includes an alpha-2-adrenergic agonist. In another embodiment, the efficacy enhancing components include fatty acids. In a preferred embodiment, the therapeutic component and the efficacy enhancing component forms a complex.

Abstract: Alpha-2-Adrenergic Agonist/Fatty Acid Compositions Compositions comprising an alpha-2-adrenergic agonist component and a fatty acid component are disclosed. In one embodiment, the fatty acid components include fatty acids. In a preferred embodiment, the alpha-2-adrenergic agonist component and the fatty acid component forms a complex.

Abstract: An instrument for implanting an elastically foldable intraocular lens in an eye is described. The instrument comprises a barrel having proximal and distal ends and a nozzle having a slender ocular insertion end region sized for insertion through an ocular incision no greater than about 3.7 mm., the nozzle being attached to the distal end of the nozzle. The barrel includes an intraocular lens holding chamber upstream of the nozzle. First and second shield elements are disposed inside along opposite side regions of the nozzle, each of the shield elements having an elastically deformable protective shield region disposed in the nozzle in an elastically deformed state.

Abstract: Compounds, compositions and methods are disclosed useful for enhancing penetration of a pharmacologically active substances across skin or tissue membranes. Compounds for use in such compositions and methods are highly water-soluble N-substituted polyalkylene oxide derivatives of cyclic amides.

Abstract: Methods for treating an injured muscle by local administration of a neurotoxin, such as a botulinum toxin, to promote healing and/or to reduce the pain associated with an injured muscle.

Abstract: The current invention relates to methods for treating hyperlipidemia in mammals, including humans. More specifically, the current invention relates to the use of retinoid or retinoid derivative that is able to act as an antagonist or inverse agonist of a retinoid receptor to treat hyperlipidemia.

Abstract: An IOL insertion apparatus including a cartridge with an IOL-receiving chamber, a handpiece into which the cartridge is loaded, and a plunger rod that extends through a lumen in the cartridge to reliably engage the IOL therein. The chamber has a recess in one wall that creates a space adjacent the proximal edge of the IOL positioned therein. A lip or projection on the plunger rod is aligned with the space to extend underneath the proximal edge of the IOL. The plunger rod may define a forked end with a groove into which the proximal edge of the IOL is captured. The cartridge may be of the type that folds the IOL therein. The recess may continue the entire length of the cartridge to guide the plunger rod therethrough. The cartridge lumen may converge so that the IOL is further compressed therealong. An inwardly-directed wall portion in the cartridge may help guide the lip of the plunger rod into the recess.

Abstract: An intraocular lens for use in a mammalian eye includes an optic adapted to focus light toward a retina of the mammalian eye and, in cooperation with the mammalian eye, to provide accommodation, the optic being adapted to have a first configuration to provide substantially a single optical power and a second configuration to provide a plurality of different optical powers.